PFO Occluder Erosion, Post-Implant Thrombosis Indicate Caution Warranted
This article was originally published in The Gray Sheet
Executive Summary
Post-implant problems associated with patent foramen ovale (PFO) and atrial septal defect (ASD) devices, including potential thrombosis and device erosion, need to be overcome before the technology can be universally applied, according to TCT participants
You may also be interested in...
NMT Set To Study Next-Generation BioStar Tissue-Based PFO Closure Device
NMT Medical plans to begin human clinical studies of its next-generation, bio-resorbable patent foramen ovale (PFO) closure device,BioStar, in the second quarter of this year
NMT Set To Study Next-Generation BioStar Tissue-Based PFO Closure Device
NMT Medical plans to begin human clinical studies of its next-generation, bio-resorbable patent foramen ovale (PFO) closure device,BioStar, in the second quarter of this year
Off-Label Practices Plague Circulatory System Device Randomized Trials
Off-label use of biliary stents is hindering superficial femoral artery (SFA) device development, CDRH Division of Cardiovascular Devices Director Bram Zuckerman told participants at CRT 2004 in Washington, D.C